Anti-PGC1 alpha antibody - N-terminal (ab191838)

Reviews (1) Submit a question References (12)

Overview

  • Product name

    Anti-PGC1 alpha antibody - N-terminal
    See all PGC1 alpha primary antibodies

  • Description

    Rabbit polyclonal to PGC1 alpha - N-terminal

  • Host species

    Rabbit

  • Specificity

    At least three isoforms of PGC1 alpha are known to exist; this antibody will detect all three isoforms.

  • Tested applications

    Suitable for: WB, IHC-P, ICC/IFmore details

  • Species reactivity

    Reacts with: Mouse, Rat, Human
    Predicted to work with: Cow, Pig

  • Immunogen

    Synthetic peptide within Human PGC1 alpha (N terminal). The exact sequence is proprietary. The immunogen is located within amino acids 200 - 250 of PGC1 alpha and consists of a 17 amino acid peptide.
    Database link: Q9UBK2

  • Positive control

    • WB: 293T, HeLa, HepG2, MCF-7, NIH-3T3 AND YB2/0 cells; Human and rat heart lysate. IHC-P: Rat heart tissue.

  • General notes

    This product may be covered by one or more of the following U.S. Patents.

    6,166,192
    6,426,411
    6,525,178
    6,872,391
    6,908,987
    7,250,283
    7,091,006
    7,354,738
    8,105,774
    8,445,233

     

Applications

Our Abpromise guarantee covers the use of ab191838 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB Use a concentration of 1 - 2 µg/ml. Predicted molecular weight: 91 kDa.
IHC-P Use a concentration of 5 - 20 µg/ml.
ICC/IF Use a concentration of 20 µg/ml.

Target

  • Function

    Transcriptional coactivator for steroid receptors and nuclear receptors. Greatly increases the transcriptional activity of PPARG and thyroid hormone receptor on the uncoupling protein promoter. Can regulate key mitochondrial genes that contribute to the program of adaptive thermogenesis. Plays an essential role in metabolic reprogramming in response to dietary availability through coordination of the expression of a wide array of genes involved in glucose and fatty acid metabolism. Induces the expression of PERM1 in the skeletal muscle in an ESRRA-dependent manner. Also involved in the integration of the circadian rhythms and energy metabolism. Required for oscillatory expression of clock genes, such as ARNTL/BMAL1 and NR1D1, through the coactivation of RORA and RORC, and metabolic genes, such as PDK4 and PEPCK.

  • Tissue specificity

    Heart, skeletal muscle, liver and kidney. Expressed at lower levels in brain and pancreas and at very low levels in the intestine and white adipose tissue. In skeletal muscle, levels were lower in obese than in lean subjects and fasting induced a 2-fold increase in levels in the skeletal muscle in obese subjects.

  • Sequence similarities

    Contains 1 RRM (RNA recognition motif) domain.

  • Post-translational
    modifications

    Phosphorylation by AMPK in skeletal muscle increases activation of its own promoter. Phosphorylated by CLK2.
    Heavily acetylated by GCN5 and biologically inactive under conditions of high nutrients. Deacetylated by SIRT1 in low nutrients/high NAD conditions.
    Ubiquitinated. Ubiquitination by RNF34 induces proteasomal degradation.

  • Cellular localization

    Cytoplasm. Nucleus; Nucleus and Nucleus. Nucleus, PML body.
  • Information by UniProt

  • Database links

    see all

  • Alternative names

    • L PGC 1alpha antibody
    • LEM6 antibody
    • Ligand effect modulator 6 antibody
    • Peroxisome proliferative activated receptor gamma coactivator 1 alpha antibody
    • Peroxisome proliferative activated receptor gamma coactivator 1 antibody
    • Peroxisome proliferator activated receptor gamma coactivator 1 alpha antibody
    • Peroxisome proliferator activated receptor gamma coactivator 1 alpha transcript variant B4 3ext antibody
    • Peroxisome proliferator activated receptor gamma coactivator 1 alpha transcript variant B4 8a antibody
    • Peroxisome proliferator activated receptor gamma coactivator 1 alpha transcript variant B4 antibody
    • Peroxisome proliferator activated receptor gamma coactivator 1 alpha transcript variant B5 antibody
    • Peroxisome proliferator activated receptor gamma coactivator 1 alpha transcript variant B5 NT antibody
    • Peroxisome proliferator-activated receptor gamma coactivator 1-alpha antibody
    • PGC 1 (alpha) antibody
    • PGC 1 alpha antibody
    • PGC 1v antibody
    • PGC-1-alpha antibody
    • PGC1 antibody
    • PGC1(alpha) antibody
    • PGC1A antibody
    • PGC1v antibody
    • PPAR gamma coactivator 1 alpha 3 ligand effect modulator 6 antibody
    • PPAR gamma coactivator 1 alpha antibody
    • PPAR gamma coactivator 1 antibody
    • PPAR gamma coactivator variant form antibody
    • PPAR-gamma coactivator 1-alpha antibody
    • PPARGC 1 alpha antibody
    • PPARGC-1-alpha antibody
    • PPARGC1 antibody
    • PPARGC1A antibody
    • PRGC1_HUMAN antibody
    see all

Images

  • Western blot - Anti-PGC1 alpha antibody - N-terminal (ab191838)
    Western blot - Anti-PGC1 alpha antibody - N-terminal (ab191838)
    All lanes : Anti-PGC1 alpha antibody - N-terminal (ab191838) at 2 µg/ml

    Lane 1 : 293T cells
    Lane 2 : HeLa cells
    Lane 3 : HepG2 cells
    Lane 4 : MCF-7 cells
    Lane 5 : NIH/3T3 cells
    Lane 6 : YB2/0 cells

    Lysates/proteins at 15 µg per lane.

    Secondary
    All lanes : Goat anti-rabbit IgG HRP conjugate at 1/10000 dilution

    Developed using the ECL technique.

    Predicted band size: 91 kDa



    Gel: 10%

    Running condition: 130V, 1.5hrs

    Transfer condition: Wet, 250mA, 2 hrs (Nitrocellulose membrane)

    Blocking condition: 5% non-fat milk in TBS at 4 overnight

    Primary antibody incubation: Room temperature for 1 hour

    Secondary antibody incubation: Room temperature for 1 hour

    Washing condition: 5 mL TBST, 4 x 5 minutes

    Exposure system: ECL 5 minutes

  • Western blot - Anti-PGC1 alpha antibody - N-terminal (ab191838)
    Western blot - Anti-PGC1 alpha antibody - N-terminal (ab191838)
    All lanes : Anti-PGC1 alpha antibody - N-terminal (ab191838) at 2 µg/ml

    Lane 1 : Human heart
    Lane 2 : Rat heart

    Lysates/proteins at 15 µg per lane.

    Secondary
    All lanes : Goat anti-rabbit IgG HRP conjugate at 1/10000 dilution

    Developed using the ECL technique.

    Predicted band size: 91 kDa



    Gel: 10%

    Running condition: 130V, 1.5hrs

    Transfer condition: Wet, 250mA, 2 hrs (Nitrocellulose membrane)

    Blocking condition: 5% non-fat milk in TBS at 4 overnight

    Primary antibody incubation: Room temperature for 1 hour

    Secondary antibody incubation: Room temperature for 1 hour

    Washing condition: 5 mL TBST, 4 x 5 minutes

    Exposure system: ECL 30 minutes

  • Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-PGC1 alpha antibody - N-terminal (ab191838)
    Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-PGC1 alpha antibody - N-terminal (ab191838)
    Immunohistochemistry (Formalin-fixed paraffin embedded sections) of rat heart tissue labeling PGC1 alpha with Anti-PGC1 alpha antibody - N-terminal (ab191838) at 5μg/ml.
  • Immunocytochemistry/ Immunofluorescence - Anti-PGC1 alpha antibody - N-terminal (ab191838)
    Immunocytochemistry/ Immunofluorescence - Anti-PGC1 alpha antibody - N-terminal (ab191838)

    Immunofluorescent analysis of rat heart tissue labeling PGC1 alpha with ab191838 at 20 µg/ml

  • Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-PGC1 alpha antibody - N-terminal (ab191838)
    Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-PGC1 alpha antibody - N-terminal (ab191838)

    Immunohistochemical analysis of rat heart tissue labeling PGC1 alpha with ab191838 at 5 µg/ml.

References

This product has been referenced in:

  • Rezzani R  et al. A carnosine analog with therapeutic potentials in the treatment of disorders related to oxidative stress. PLoS One 14:e0215170 (2019). Read more (PubMed: 30964920) »
  • Wen J  et al. Protective effects of higenamine combined with [6]-gingerol against doxorubicin-induced mitochondrial dysfunction and toxicity in H9c2 cells and potential mechanisms. Biomed Pharmacother 115:108881 (2019). Read more (PubMed: 31028997) »
See all 12 Publications for this product

Publishing research using ab191838? Please let us know so that we can cite the reference in this datasheet.

Customer reviews and Q&As

Show All Reviews Q&A
Submit a review Submit a question

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) abreview for Anti-PGC1 alpha antibody - N-terminal

 Excellent
Abreviews
abreview image
Application
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)
Sample
Rat Tissue sections (Heart)
Antigen retrieval step
Heat mediated - Buffer/Enzyme Used: Tris-EDTA pH 9.0
Permeabilization
Yes - 0.025% Triton x-100
Specification
Heart
Blocking step
BSA as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 3% · Temperature: 37°C
Fixative
Paraformaldehyde
Read More

Abcam user community

Verified customer

Submitted Sep 09 2015

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
For licensing inquiries, please contact partnerships@abcam.com